News coverage about Athenex (NASDAQ:ATNX) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Athenex earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.2573534956072 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle Nasdaq:ATNX (menafn.com)
- Athenex (ATNX) Reports Planned Retirement of CFO Nick Riehle (streetinsider.com)
- Athenex, Inc. breached its 50 day moving average in a Bearish Manner : ATNX-US : December 1, 2017 (finance.yahoo.com)
- ETFs with exposure to Athenex, Inc. : November 30, 2017 (finance.yahoo.com)
Athenex (NASDAQ:ATNX) opened at $17.03 on Friday. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
What are top analysts saying about Athenex Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Athenex Inc and related companies.